Objective To address the personalized differences in motion gait between stroke patients and healthy older adults,as well as the issue of abnormal gait recognition,a deep learning fusion-based approach is proposed to effectively improve the accuracy of abnormal gait recognition.Methods A model fusing convolutional neural networks(CNN)and bidirectional long short-term memory networks(BiLSTM)was adopted,with the introduction of a residual network(ResNet).Unilateral ankle joint movement data at different walking speeds within a comfortable range were collected from healthy older adults and stroke patients.Signals from inertial sensors and electromyography sensors were used as inputs,while gait features were analyzed and gait differences between the two groups were compared.The effectiveness of the model was validated by comparing the classification performance of traditional deep learning models and CNN-ResNet-BiLSTM models with different layer combinations in terms of abnormal gait recognition accuracy.Results The CNN-ResNet-BiLSTM model,which introduced residual connectivity,performed excellently in abnormal gait recognition.Compared with traditional deep learning models such as the gated recurrent unit(GRU)and long short-term memory network(LSTM),its prediction accuracy was improved by 13.6％and 8.36％,respectively.Additionally,compared with other model combinations,this model achieved an overall accuracy of 97.78％.Conclusions The algorithm proposed in this study can be applied to stroke-related abnormal gait detection,providing technique support for the early diagnosis and precise monitoring of such diseases.

Objective:To investigate the risk factors associated with preoperative heart failure in elderly patients with intertrochanteric fracture and evaluate their predictive efficacy.Methods:A retrospective cohort study was conducted to analyze the clinical data of 163 elderly patients with intertrochanteric fracture admitted to the Affiliated Drum Tower Hospital of Nanjing University School of Medicine from July 2018 to July 2022, including 57 males and 106 females, aged 63-98 years [83.3(78.0, 87.0)years]. The patients were divided into high-risk heart failure group ( n=66) and non-high-risk group ( n=97) based on whether the serum B-type natriuretic peptide (BNP) level within 24 hours on admission was greater than 100 pg/ml. The following data in the two groups were collected, including gender, age, AO/OTA fracture classification, fracture laterality, associated underlying comorbidities (diabetes, cardiovascular diseases, cerebral infarction), past history of fracture, history of surgeries, time from injury to hospitalization less than 48 hours, first blood pressure on admission, first routine blood test on admission [leukocyte count (WBC), neutrophil count (NEUT), lymphocyte count, platelet (PLT), hemoglobin (Hb)], first blood biochemistry on admission [alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), albumin, glucose, serum calcium, creatinine, glomerular filtration rate (GFR), and first other related tests on admission [D-dimer, prothrombin time (PT), C-reactive protein (CRP)]. Independent risk factors for preoperative heart failure in elderly patients with intertrochanteric fracture were identified through univariate analysis and binary logistic regression analysis. The predictive efficacy of each indicator or two combined indicators for preoperative heart failure in elderly patients with intertrochanteric fractures was assessed by plotting the receiver operating characteristic (ROC) curve and calculating the area under the curve (AUC). Results:Univariate analysis demonstrated that age, associated cardiovascular diseases, history of fracture, time from injury to hospitalization less than 48 hours, Hb, creatinine and GFR were significantly correlated with the preoperative heart failure ( P<0.05), while gender, AO/OTA fracture classification, fracture laterality, diabetes, cerebral infarction, history of surgeries, blood pressure, WBC, NEUT, lymphocyte count, PLT, CRP, ALT, AST, LDH, albumin, glucose, serum calcium, D-dimer, PT, and CRP were not correlated with the preoperative heart failure in elderly patients with intertrochanteric fractures ( P>0.05). Logistic regression analysis revealed that age (95% CI 1.02, 1.15, P<0.05), associated cardiovascular disease (95% CI 1.31, 5.88, P<0.01), Hb (95% CI 0.96, 1.00, P<0.05), and GFR (95% CI 0.97, 1.00, P<0.05) were independent risk factors for heart failure in elderly patients with intertrochanteric fracture. ROC curve analysis demonstrated that age, associated cardiovascular diseases, Hb, and GFR could predict preoperative heart failure in elderly patients with intertrochanteric fractures, with the combination of associated cardiovascular disease and GFR showing a relatively higher predictive ability (AUC=0.76, 95% CI 0.68, 0.84). Conclusions:Age, associated cardiovascular diseases, Hb and GFR are independent risk factors for preoperative heart failure in elderly patients with intertrochanteric fracture. Moreover, the combination of associated cardiovascular diseases and GFR possesses a relatively higher predictive value for preoperative heart failure in elderly patients with intertrochanteric fracture.

With the main pathological features of glomerulosclerosis and interstitial fibrosis， renal fibrosis is a key pathological process causing chronic kidney disease to progress to end-stage disease. As a cellular autophagic process， mitochondrial autophagy plays a crucial role in maintaining mitochondrial mass and functional stability. Mitochondrial dysfunction is considered to be one of the key factors driving the progression of fibrosis. Phosphatase and tension protein homologue （PTEN） induce various signalling pathways such as putative kinase 1/parkin， Nip3-like protein X/Bcl-2 interacting protein 3， and FUN14 structural domain-containing protein 1 to activate mitochondrial autophagy to participate in the regulation of fibrogenic factors， amelioration of oxidative stress， and inhibition of inflammatory response and apoptosis， which in turn effectively slows down the progression of renal fibrosis. Studies have shown that traditional Chinese medicine monomers and compound preparations， including phenolics， terpenoids， ketones， and alkaloids， can regulate mitochondrial autophagy-related signalling pathways and achieve significant clinical efficacy in intervening in the progression of renal fibrosis for the treatment of chronic kidney disease. This paper summarized the mechanism of mitochondrial autophagy and the research progress of traditional Chinese medicine intervention in renal fibrosis to provide new ideas for the study of the mechanism of traditional Chinese medicine in treating renal fibrosis.

With the main pathological features of glomerulosclerosis and interstitial fibrosis， renal fibrosis is a key pathological process causing chronic kidney disease to progress to end-stage disease. As a cellular autophagic process， mitochondrial autophagy plays a crucial role in maintaining mitochondrial mass and functional stability. Mitochondrial dysfunction is considered to be one of the key factors driving the progression of fibrosis. Phosphatase and tension protein homologue （PTEN） induce various signalling pathways such as putative kinase 1/parkin， Nip3-like protein X/Bcl-2 interacting protein 3， and FUN14 structural domain-containing protein 1 to activate mitochondrial autophagy to participate in the regulation of fibrogenic factors， amelioration of oxidative stress， and inhibition of inflammatory response and apoptosis， which in turn effectively slows down the progression of renal fibrosis. Studies have shown that traditional Chinese medicine monomers and compound preparations， including phenolics， terpenoids， ketones， and alkaloids， can regulate mitochondrial autophagy-related signalling pathways and achieve significant clinical efficacy in intervening in the progression of renal fibrosis for the treatment of chronic kidney disease. This paper summarized the mechanism of mitochondrial autophagy and the research progress of traditional Chinese medicine intervention in renal fibrosis to provide new ideas for the study of the mechanism of traditional Chinese medicine in treating renal fibrosis.

Ursodeoxycholic acid(UDCA)is a naturally occurring,low-toxicity,and hydrophilic bile acid(BA)in the human body that is converted by intestinal flora using primary BA.Solute carrier family 7 member 11(SLC7A11)functions to uptake extracellular cystine in exchange for glutamate,and is highly expressed in a variety of human cancers.Retroperitoneal liposarcoma(RLPS)refers to liposarcoma originating from the retroperitoneal area.Lipidomics analysis revealed that UDCA was one of the most significantly down-regulated metabolites in sera of RIPS patients compared with healthy subjects.The augmentation of UDCA concentration(≥25 μg/mL)demonstrated a suppressive effect on the proliferation of liposarcoma cells.[15N2]-cystine and[13Cs]-glutamine isotope tracing revealed that UDCA impairs cystine uptake and glutathione(GSH)synthesis.Mechanistically,UDCA binds to the cystine transporter SLC7A11 to inhibit cystine uptake and impair GSH de novo synthesis,leading to reactive oxygen species(ROS)accumulation and mitochondrial oxidative damage.Furthermore,UDCA can promote the anti-cancer effects of ferroptosis inducers(Erastin,RSL3),the murine double minute 2(MDM2)inhibitors(Nutlin 3a,RG7112),cyclin dependent kinase 4(CDK4)inhibitor(Abemaciclib),and glutaminase inhibitor(CB839).Together,UDCA functions as a cystine exchange factor that binds to SLC7A11 for antitumor activity,and SLC7A11 is not only a new transporter for BA but also a clinically applicable target for UDCA.More importantly,in combination with other antitumor chemotherapy or physiotherapy treatments,UDCA may provide effective and promising treatment strategies for RLPS or other types of tumors in a ROS-dependent manner.

Ursodeoxycholic acid (UDCA) is a naturally occurring, low-toxicity, and hydrophilic bile acid (BA) in the human body that is converted by intestinal flora using primary BA. Solute carrier family 7 member 11 (SLC7A11) functions to uptake extracellular cystine in exchange for glutamate, and is highly expressed in a variety of human cancers. Retroperitoneal liposarcoma (RLPS) refers to liposarcoma originating from the retroperitoneal area. Lipidomics analysis revealed that UDCA was one of the most significantly downregulated metabolites in sera of RLPS patients compared with healthy subjects. The augmentation of UDCA concentration (≥25 μg/mL) demonstrated a suppressive effect on the proliferation of liposarcoma cells. [¹⁵N₂]-cystine and [¹³C₅]-glutamine isotope tracing revealed that UDCA impairs cystine uptake and glutathione (GSH) synthesis. Mechanistically, UDCA binds to the cystine transporter SLC7A11 to inhibit cystine uptake and impair GSH de novo synthesis, leading to reactive oxygen species (ROS) accumulation and mitochondrial oxidative damage. Furthermore, UDCA can promote the anti-cancer effects of ferroptosis inducers (Erastin, RSL3), the murine double minute 2 (MDM2) inhibitors (Nutlin 3a, RG7112), cyclin dependent kinase 4 (CDK4) inhibitor (Abemaciclib), and glutaminase inhibitor (CB839). Together, UDCA functions as a cystine exchange factor that binds to SLC7A11 for antitumor activity, and SLC7A11 is not only a new transporter for BA but also a clinically applicable target for UDCA. More importantly, in combination with other antitumor chemotherapy or physiotherapy treatments, UDCA may provide effective and promising treatment strategies for RLPS or other types of tumors in a ROS-dependent manner.

Objective:To investigate the effects of different doses of rosuvastatin on lipid metabolism and left ventricular function in patients with type 2 diabetes mellitus (T2DM) accompanied by coronary heart disease (CHD).Methods:A prospective study was conducted involving 63 patients with T2DM accompanied by CHD who were treated at Jinan 2 nd People's Hospital and The Fifth People's Hospital of Jinan from January 2022 to June 2023. In a randomized case-control study, patients were assigned to either a control group ( n = 31, receiving 10 mg/d of rosuvastatin) or an observation group ( n = 32, receiving 20 mg/d of rosuvastatin) using a random number table method. After 8 weeks of treatment, the therapeutic effects were evaluated, and blood lipid levels and left ventricular function were recorded before and after treatment. Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), homocysteine (Hcy), C-reactive protein (CRP), and the distance covered in a 6-minute walk test were compared between the two groups. Patients were followed for 1 year to monitor adverse reactions and the occurrence of adverse cardiovascular events. Results:The effective treatment rate in the observation group was significantly higher than that in the control group [90.63% (29/32) vs. 70.97% (22/31), χ2 = 3.95, P < 0.05). Prior to treatment, there were no statistically significant differences between the two groups regarding blood lipid levels, cardiac ultrasound indicators, serum levels of NT-proBNP, Hcy, and CRP, the distance covered in the 6-minute walk test, and the incidences of adverse reactions and adverse cardiovascular events (all P > 0.05). After treatment, both groups showed a reduction in total cholesterol and low-density lipoprotein cholesterol (both P < 0.05), with the observation group demonstrating significantly lower levels ( t = 10.54, 14.01, both P < 0.001). Additionally, both groups showed an increase in high-density lipoprotein cholesterol ( P < 0.05), but the observation group achieved significantly higher levels ( t = -14.07, P < 0.001). Both groups also exhibited an increase in left ventricular ejection fraction ( P < 0.05), with a greater improvement in the observation group ( t = -2.34, P < 0.05). The left ventricular end-diastolic diameter decreased in both groups ( P < 0.05), but the observation group had a smaller diameter ( t = 2.78, P < 0.05). Levels of NT-proBNP, Hcy, and CRP decreased in both groups (all P < 0.05), with the observation group showing significantly lower levels ( t = 6.55, 3.94, 6.38, all P < 0.001). Finally, the distance covered in the 6-minute walk test increased in both groups ( P < 0.05), with the observation group covering a greater distance ( t = -4.32, P < 0.001). Conclusions:High-dose rosuvastatin can effectively improve lipid metabolism and left ventricular function in patients with T2DM complicated by CHD. It significantly reduces levels of NT-proBNP, Hcy, and CRP, enhances exercise capacity, and demonstrates high safety, indicating a high potential for clinical application.

Objective To address the personalized differences in motion gait between stroke patients and healthy older adults,as well as the issue of abnormal gait recognition,a deep learning fusion-based approach is proposed to effectively improve the accuracy of abnormal gait recognition.Methods A model fusing convolutional neural networks(CNN)and bidirectional long short-term memory networks(BiLSTM)was adopted,with the introduction of a residual network(ResNet).Unilateral ankle joint movement data at different walking speeds within a comfortable range were collected from healthy older adults and stroke patients.Signals from inertial sensors and electromyography sensors were used as inputs,while gait features were analyzed and gait differences between the two groups were compared.The effectiveness of the model was validated by comparing the classification performance of traditional deep learning models and CNN-ResNet-BiLSTM models with different layer combinations in terms of abnormal gait recognition accuracy.Results The CNN-ResNet-BiLSTM model,which introduced residual connectivity,performed excellently in abnormal gait recognition.Compared with traditional deep learning models such as the gated recurrent unit(GRU)and long short-term memory network(LSTM),its prediction accuracy was improved by 13.6％and 8.36％,respectively.Additionally,compared with other model combinations,this model achieved an overall accuracy of 97.78％.Conclusions The algorithm proposed in this study can be applied to stroke-related abnormal gait detection,providing technique support for the early diagnosis and precise monitoring of such diseases.

Objective:To investigate the effects of different doses of rosuvastatin on lipid metabolism and left ventricular function in patients with type 2 diabetes mellitus (T2DM) accompanied by coronary heart disease (CHD).Methods:A prospective study was conducted involving 63 patients with T2DM accompanied by CHD who were treated at Jinan 2 nd People's Hospital and The Fifth People's Hospital of Jinan from January 2022 to June 2023. In a randomized case-control study, patients were assigned to either a control group ( n = 31, receiving 10 mg/d of rosuvastatin) or an observation group ( n = 32, receiving 20 mg/d of rosuvastatin) using a random number table method. After 8 weeks of treatment, the therapeutic effects were evaluated, and blood lipid levels and left ventricular function were recorded before and after treatment. Plasma levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), homocysteine (Hcy), C-reactive protein (CRP), and the distance covered in a 6-minute walk test were compared between the two groups. Patients were followed for 1 year to monitor adverse reactions and the occurrence of adverse cardiovascular events. Results:The effective treatment rate in the observation group was significantly higher than that in the control group [90.63% (29/32) vs. 70.97% (22/31), χ2 = 3.95, P < 0.05). Prior to treatment, there were no statistically significant differences between the two groups regarding blood lipid levels, cardiac ultrasound indicators, serum levels of NT-proBNP, Hcy, and CRP, the distance covered in the 6-minute walk test, and the incidences of adverse reactions and adverse cardiovascular events (all P > 0.05). After treatment, both groups showed a reduction in total cholesterol and low-density lipoprotein cholesterol (both P < 0.05), with the observation group demonstrating significantly lower levels ( t = 10.54, 14.01, both P < 0.001). Additionally, both groups showed an increase in high-density lipoprotein cholesterol ( P < 0.05), but the observation group achieved significantly higher levels ( t = -14.07, P < 0.001). Both groups also exhibited an increase in left ventricular ejection fraction ( P < 0.05), with a greater improvement in the observation group ( t = -2.34, P < 0.05). The left ventricular end-diastolic diameter decreased in both groups ( P < 0.05), but the observation group had a smaller diameter ( t = 2.78, P < 0.05). Levels of NT-proBNP, Hcy, and CRP decreased in both groups (all P < 0.05), with the observation group showing significantly lower levels ( t = 6.55, 3.94, 6.38, all P < 0.001). Finally, the distance covered in the 6-minute walk test increased in both groups ( P < 0.05), with the observation group covering a greater distance ( t = -4.32, P < 0.001). Conclusions:High-dose rosuvastatin can effectively improve lipid metabolism and left ventricular function in patients with T2DM complicated by CHD. It significantly reduces levels of NT-proBNP, Hcy, and CRP, enhances exercise capacity, and demonstrates high safety, indicating a high potential for clinical application.

Objective:To investigate the risk factors associated with preoperative heart failure in elderly patients with intertrochanteric fracture and evaluate their predictive efficacy.Methods:A retrospective cohort study was conducted to analyze the clinical data of 163 elderly patients with intertrochanteric fracture admitted to the Affiliated Drum Tower Hospital of Nanjing University School of Medicine from July 2018 to July 2022, including 57 males and 106 females, aged 63-98 years [83.3(78.0, 87.0)years]. The patients were divided into high-risk heart failure group ( n=66) and non-high-risk group ( n=97) based on whether the serum B-type natriuretic peptide (BNP) level within 24 hours on admission was greater than 100 pg/ml. The following data in the two groups were collected, including gender, age, AO/OTA fracture classification, fracture laterality, associated underlying comorbidities (diabetes, cardiovascular diseases, cerebral infarction), past history of fracture, history of surgeries, time from injury to hospitalization less than 48 hours, first blood pressure on admission, first routine blood test on admission [leukocyte count (WBC), neutrophil count (NEUT), lymphocyte count, platelet (PLT), hemoglobin (Hb)], first blood biochemistry on admission [alanine aminotransferase (ALT), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), albumin, glucose, serum calcium, creatinine, glomerular filtration rate (GFR), and first other related tests on admission [D-dimer, prothrombin time (PT), C-reactive protein (CRP)]. Independent risk factors for preoperative heart failure in elderly patients with intertrochanteric fracture were identified through univariate analysis and binary logistic regression analysis. The predictive efficacy of each indicator or two combined indicators for preoperative heart failure in elderly patients with intertrochanteric fractures was assessed by plotting the receiver operating characteristic (ROC) curve and calculating the area under the curve (AUC). Results:Univariate analysis demonstrated that age, associated cardiovascular diseases, history of fracture, time from injury to hospitalization less than 48 hours, Hb, creatinine and GFR were significantly correlated with the preoperative heart failure ( P<0.05), while gender, AO/OTA fracture classification, fracture laterality, diabetes, cerebral infarction, history of surgeries, blood pressure, WBC, NEUT, lymphocyte count, PLT, CRP, ALT, AST, LDH, albumin, glucose, serum calcium, D-dimer, PT, and CRP were not correlated with the preoperative heart failure in elderly patients with intertrochanteric fractures ( P>0.05). Logistic regression analysis revealed that age (95% CI 1.02, 1.15, P<0.05), associated cardiovascular disease (95% CI 1.31, 5.88, P<0.01), Hb (95% CI 0.96, 1.00, P<0.05), and GFR (95% CI 0.97, 1.00, P<0.05) were independent risk factors for heart failure in elderly patients with intertrochanteric fracture. ROC curve analysis demonstrated that age, associated cardiovascular diseases, Hb, and GFR could predict preoperative heart failure in elderly patients with intertrochanteric fractures, with the combination of associated cardiovascular disease and GFR showing a relatively higher predictive ability (AUC=0.76, 95% CI 0.68, 0.84). Conclusions:Age, associated cardiovascular diseases, Hb and GFR are independent risk factors for preoperative heart failure in elderly patients with intertrochanteric fracture. Moreover, the combination of associated cardiovascular diseases and GFR possesses a relatively higher predictive value for preoperative heart failure in elderly patients with intertrochanteric fracture.